ArticleInsights into imaging2025
Explainable multi-modal radiomics for early prediction of liver metastasis in rectal cancer: a multicentric study.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence for the prediction of synchronous and metachronous liver metastasis in colorectal cancer patients: a systematic review and meta-analysis.Abdominal radiology (New York) · 2026Pooled it
- Radiomics' Role in Predicting Distant Metastases, Recurrence and Survival Outcome in Rectal Cancer: A Systematic Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo enhance liver metastasis (LM) risk prediction for rectal cancer (RC) patients using a multi-modal, explainable radiomics model based on rectal MRI and whole-liver CT, and to assess its prognostic value for survival.
methodsThis retrospective study enrolled patients with pathologically confirmed RC from two medical centers. Radiomics features were extracted from rectal MRI as well as pre-metastatic liver CT. Feature selection was performed using ANOVA F-value and recursive feature elimination. The SHAP method elucidated the model's functionality by highlighting key feature contributions. Finally, Kaplan-Meier survival analysis and Cox regression assessed the prognostic utility of the model's prediction score.
resultsA total of 431 patients were enrolled from two centers in our study. The radiomics model developed from baseline whole-liver CT features alone could predict LM development in all cohorts. A fusion model integrating liver CT with primary tumor MRI features provided synergetic effect and was more efficient in predicting LM, displaying an area under the receiver operating curve (AUC) of 0.85 (95% CI: 0.80-0.90) in the training cohort, and AUC values of 0.75 (95% CI: 0.64-0.86) and 0.73 (95% CI: 0.61-0.85) in the internal and external validation cohorts, respectively. SHAP summary plots illustrated how feature values influenced their impact on the model. The risk score generated by our model demonstrated significant prognostic value for LM-free survival (LMFS).
conclusionsThe multi-modal, explainable radiomics model integrating primary tumor and pre-metastatic liver radiomics enhances the prediction of LM development and provides prognostic value in RC patients. CRITICAL RELEVANCE STATEMENT: This study demonstrates that integrating radiomics features from pre-metastatic liver and primary tumors enhances the predictive performance for liver metastasis development in rectal cancer patients, highlighting its potential for personalized treatment planning and follow-up strategies for rectal cancer patients. KEY POINTS: Pre-metastatic liver CT radiomics features could predict the liver metastasis development of rectal cancer. Integrating primary tumor and pre-metastatic liver radiomics improved liver metastasis prediction accuracy. The model demonstrated favorable interpretability through SHAP method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.